CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 51 enrolled
Drug / intervention
Mometasone furoate nasal spray (MFNS) +1 moredrug
Likely dose
Mometasone furoate nasal spray (MFNS) 200 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00599027
NCT00599027Phase 3Completed
CompareCT.gov

An Exploratory Study of Mometasone Furoate Nasal Spray in Patients With Moderate-severe Persistent Allergic Rhinitis and Intermittent Asthma: Effects on the Quality of Life Evaluated With the Rhinasthma Questionnaire

Organon and Co·interventional·Posted Jan 23, 2008·Updated May 21, 2024

In Brief

A Phase 3 clinical trial evaluating Mometasone furoate nasal spray (MFNS) and Placebo nasal spray for Allergic Rhinitis and Asthma. Completed, enrolled 51 participants.

Detailed Summary

The primary objective of this study is to explore the efficacy of Nasonex (mometasone furoate nasal spray) in comparison with placebo in improving the quality of life of subjects with moderate to severe persistent allergic rhinitis and intermittent asthma. A secondary objective is to evaluate the efficacy of Nasonex in relieving the subject's symptoms of allergic rhinitis and asthma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Rhinitis, Asthma
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 23, 2008
Enrollment StartMay 1, 2008
Primary CompletionMay 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 18.4 years ago

Interventions

Mometasone furoate nasal spray (MFNS)drug

Mometasone furoate nasal spray (MFNS) 200 mcg once daily (two 50 mcg puffs per nostril) in the morning.

Placebo nasal spraydrug

Placebo nasal spray once daily (two puffs per nostril) in the morning.